Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies
- PMID: 38717677
- PMCID: PMC11078801
- DOI: 10.1007/s00432-024-05755-w
Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies
Abstract
Colitis-associated colorectal cancer has been a hot topic in public health issues worldwide. Numerous studies have demonstrated the significance of myeloid-derived suppressor cells (MDSCs) in the progression of this ailment, but the specific mechanism of their role in the transformation of inflammation to cancer is unclear, and potential therapies targeting MDSC are also unclear. This paper outlines the possible involvement of MDSC to the development of colitis-associated colorectal cancer. It also explores the immune and other relevant roles played by MDSC, and collates relevant targeted therapies against MDSC. In addition, current targeted therapies for colorectal cancer are analyzed and summarized.
Keywords: CRC; Colitis-associated colorectal cancer; MDSC; Targeting strategies.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.Klin Onkol. 2018 Winter;31(Suppl 2):88-92. Klin Onkol. 2018. PMID: 31023030 English.
-
MDSCs are involved in the protumorigenic potentials of GM-CSF in colitis-associated cancer.Int J Immunopathol Pharmacol. 2017 Jun;30(2):152-162. doi: 10.1177/0394632017711055. Epub 2017 May 23. Int J Immunopathol Pharmacol. 2017. PMID: 28534709 Free PMC article.
-
Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.Invest New Drugs. 2022 Jun;40(3):506-518. doi: 10.1007/s10637-022-01218-6. Epub 2022 Jan 28. Invest New Drugs. 2022. PMID: 35089465 Free PMC article.
-
Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer.J Immunother Cancer. 2020 Oct;8(2):e000609. doi: 10.1136/jitc-2020-000609. J Immunother Cancer. 2020. PMID: 33051339 Free PMC article. Review.
-
Myeloid-Derived Suppressor Cells in Colorectal Cancer.Front Immunol. 2020 Aug 7;11:1526. doi: 10.3389/fimmu.2020.01526. eCollection 2020. Front Immunol. 2020. PMID: 32849517 Free PMC article. Review.
References
-
- André T, Falcone A, Shparyk Y, Moiseenko F, Polo-Marques E, Csöszi T, Saunders MP. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol. 2023;8(2):133–144. doi: 10.1016/s2468-1253(22)00334-x. - DOI - PubMed
-
- Boige V, Blons H, François E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, Bouché O. Maintenance therapy with cetuximab after FOLFIRI plus cetuximab for ras wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Netw Open. 2023;6(9):e2333533. doi: 10.1001/jamanetworkopen.2023.33533. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical